D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX)
D. Boral Capital reissued a "buy" rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Thursday...
MarketBeat·12h ago
More News
ImmunityBio (NASDAQ:IBRX) Sees Large Volume Increase - Still a Buy?
ImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volume - What's Next...
MarketBeat·9d ago
ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's Why
ImmunityBio (NASDAQ:IBRX) Shares Gap Up - What's Next...
MarketBeat·12d ago
AlphaCore Capital LLC Takes $7.85 Million Position in ImmunityBio, Inc. $IBRX
AlphaCore Capital LLC purchased a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·20d ago
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
Key PointsBought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value...
Nasdaq News: Markets·22d ago
ImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $24.00 target price on shares of ImmunityBio in a research report on Thursday...
MarketBeat·27d ago
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical...
Business Wire·29d ago
Analysts Set Expectations for ImmunityBio FY2025 Earnings
ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for shares of ImmunityBio in a report released on Wednesday...
MarketBeat·1mo ago
HC Wainwright Increases Earnings Estimates for ImmunityBio
ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Investment analysts at HC Wainwright lifted their FY2029 earnings per share (EPS) estimates for shares of ImmunityBio in a research report issued to...
MarketBeat·1mo ago
ImmunityBio (NASDAQ:IBRX) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reissued a "buy" rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Wednesday...